INS and metabolic disease: The administration of resveratrol considerably restrains the fall of serum melatonin, reduces serum TNF-α and CRP levels, blood MDA-TBA2, serum glucose and insulin concentrations, HOMA-IR, serum VLDL, and TAG levels, increases serum HDL, and thereby prevents pro-inflammatory activities, LPO and metabolic disorder, as well as improving general antioxidant blood potential in rats fed a high-fructose high-lipid diet under round-the-clock lighting.